Posterior capsule opacification (PCO) is a frequent and important complication noticed in diabetics undergoing cataract surgery, however, few studies have examined the prevalence of PCO in diabetic versus non-diabetic patients. Therefore, the authors performed a study exploring the long-term effect of diabetes on the incidence of PCO and here they highlight their findings.
The National Aeronautics and Space Administration (NASA) Ocular Health Study has been named as the recipient of Heidelberg Engineering's 2014 Xtreme Research Award.
A single, 1.0 or 2.0 mg intravitreal injection of the designed ankyrin repeat protein (DARPin) MP0112 showed promising efficacy and long-term duration in a trial of patients with age-related macular degeneration (AMD).
When people sleep with their heads elevated 20 degrees, their nocturnal IOP is lower than when they sleep with their heads flat, finds a newly published study.
Optical coherence tomography (OCT) can be used to characterize the angle and topography of the corneoscleral junction, according to newly published research.
Bayer HealthCare has applied to the EMA for marketing authorization of aflibercept solution for injection for the treatment of patients with visual impairment caused by macular oedema secondary to BRVO.
Increased blood pressure contributes to elevated IOP and possibly the development of glaucoma, according to the findings of a recent meta-analysis.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for brinzolamide 10 mg/mL and brimonidine tartrate 2 mg/mL eye drops suspension (Simbrinza, Alcon) to decrease elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension, for whom monotherapy provides insufficient IOP reduction.
Taking vasodilators may increase the risk of developing early-stage age-related macular degeneration (AMD), according to a study published online.
Bromfenac ophthalmic solution 0.07% (Pro-Lensa, Bausch + Lomb) used once a day results in zero-to-trace (0–5 cells) cell severity in the anterior chamber following cataract surgery with implantation of a posterior chamber IOL, according to newly published research.
Dropper bottles are the delivery vehicle of choice of patients using autologous serum eye drops daily for severe ocular surface disorders, according to a newly published study.
Patients who have macular oedema secondary to branch retinal vein occlusion (BRVO) see improved anatomic and functional outcomes with combined intravitreal bevacizumab (IVB) and intravitreal triamcinolone acetate (IVT) therapy when it is delivered early in the disease process, according to the findings of recently published research.
Implantation of two trabecular micro-bypass devices (iStent inject, Glaukos) reduced intraocular pressure (IOP) at least as effectively as a fixed combination of latanoprost/timolol in patients who had open-angle glaucoma that was not controlled by one medication, according to a recent study.
Environmental factors have been discussed as possible triggers for diseases. Recently, the authors analysed the impact of seasonality and distinct meteorological parameters on refractive and visual outcome of LASIK in myopic eyes, here, they present the highlight of this study.
Dry age-related macular degeneration (AMD) is the most common cause of vision loss in developed countries. Although anti-VEGFs can be used to improve the quality of life for patients with the wet form of the disease there is still not much to offer dry AMD patients. In this article, Dr Georgiou highlights the results of his recent study looking at the value of higher doses of omega-3 fatty acids for this group of patients.
Results of a study comparing matched groups of eyes undergoing myopic correction by small-incision lenticule extraction (SMILE) or LASIK show that the optical quality was better and the cornea retained higher tensile strength after the flapless SMILE procedure.
In this article, the authors present the highlights of their research into a new blade design for pars plana vitrectomy.
Products
Numerous trials assessing the efficacy and safety of anti-VEGFs in adults exist, however, the clinical evidence and basic science research of anti-VEGF use in infants is lacking, according to Dr Drenser. Here, she discusses what is required from future studies to justify the use of anti-VEGFs in young patients.
In this article, the authors discuss their study that was aimed at evaluating the rotational stability and patient visual quality of a toric IOL with a novel haptic design.
In this article, Dr Schallhorn reveals the results of a large case series that provides evidence that there is no need to reject candidates for LASIK on the basis of pupil size or to increase the treatment zone size for such patients.
ALG-1001 is the first of a new class of drugs, integrin peptide therapy, now going through clinical trials for patients with age-related macular degeneration, diabetic macular oedema and vitreomacular traction.
Prof. Iester describes his recent study investigating whether the addition of a tear substitute would protect exposed corneal epithelial cells from damage.
In this article, the authors summarize a recently published case study of a macular hole formation and its spontaneous closure after vitrectomy.
With a greater understanding of how ocular nutrition affects sight, ophthalmologists need to encourage healthy diets with nutrients and antioxidants essential for healthy vision.
Findings from recent clinical trials are providing some guidance on oxygen management in preterm infants.
Postoperative refractive outcome shifts toward myopia in patients being treated for rhegmatogenous retinal detachment (RRD) with the combination of phacoemulsification and pars plana vitrectomy, compared with patients who underwent combined surgery for other vitreoretinal pathologies
Radiused phacoemulsification tips were less efficient than non-radiused tips when used with torsional ultrasound (US), according to an experimental study.
Micropulse diode transscleral cyclophotocoagulation (TSCPC) lowers IOP consistently, predictably, and with minimal ocular complications, according to a recently published study.
A Phase II dose-ranging study has been initiated for Amakem Therapeutics? glaucoma drug candidate AMA0076, a highly potent, locally acting Rho Kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) while minimizing common ROCK inhibitor side effects such as hyperaemia.